JP2012524119A - C−ピラジン−メチルアミンの調製 - Google Patents
C−ピラジン−メチルアミンの調製 Download PDFInfo
- Publication number
- JP2012524119A JP2012524119A JP2012507282A JP2012507282A JP2012524119A JP 2012524119 A JP2012524119 A JP 2012524119A JP 2012507282 A JP2012507282 A JP 2012507282A JP 2012507282 A JP2012507282 A JP 2012507282A JP 2012524119 A JP2012524119 A JP 2012524119A
- Authority
- JP
- Japan
- Prior art keywords
- reaction
- diarylimine
- alkyl
- formula
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Description
いくつかの態様において、工程(a)において、ジアリールイミンは、反応A:
式中、R2は、C1-C10アルキルであり;(b)(a)のジアリールイミン生成物および2,3-ジクロロピラジンを塩基の存在下において共に反応させ;および(c)(b)の生成物を加水分解させてR1がHである式Iの化合物を得る。
式中、R3は、C1-C10アルキル、C3-C12シクロアルキル、アリールまたはヘテロアリールであり、これらのいずれもがハロ、オキソ、シアノ、ヒドロキシおよびC1-C10アルキルから選択される1つまたは複数の独立した置換基によって任意に置換され;およびR4は、ヒドロキシ、アルコキシ、クロロまたはイミダゾールである。
1H NMR (400 MHz, CDCl3) δ ppm 3.83 (s, 3H), 3.87 (s, 3H), 4.83 (s, 2H), 6.83-6.91 (m, 2H), 6.94 - 7.03 (m, 2H), 7.14-7.22 (m, 2H), 7.40-7.58 (m, 4H), 7.65- 7.74 (m, 2H), 7.75- 7.87 (m, 2H), 8.07-8.23 (m, 4H). 参照文献: N. Sotomayor Tetrahedron, 1994 , 50, 2207
加水分解のための代わりのアプローチにおいて、機械的撹拌器、N2入口/出口および温度計を備えた72Lの丸底フラスコに、トルエン中の上の実施例6において生成したものなどの粗製ピラジンイミン化合物などの溶液(〜30 L、29.9mol)を充填した。水(12L)および濃HCl(3.2L、32.9mol)を添加して、反応混合物を3時間の間、外界温度にて撹拌した(TLCによってモニターした)。層を分離して、水層をトルエン(15L)で抽出した。
本明細書に使用される、「アリール」という用語は、完全に共役したパイ電子系を有する6〜12炭素原子の全て炭素の単環式、二環式または多環式の基をいう。アリールの例は、フェニル、4-クロロフェニル、4-フルオロフェニル、4-ブロモフェニル、3-ニトロフェニル、2-メトキシフェニル、2-メチルフェニル、3-メチルフェニル、4-メチルフェニル、4-エチルフェニル、2-メチル-3-メトキシフェニル、2,4-ジブロモフェニル、3,5-ジフルオロフェニル、3,5-ジメチルフェニル、2,4,6-トリクロロフェニル、4-メトキシフェニル、ナフチル、2-クロロナフチル、2,4-ジメトキシフェニル、4-(トリフルオロメチル)フェニルおよび2-ヨード-4-メチルフェニルを含むが、限定されない。
表1−略語
Claims (23)
- 反応Bを使用してジアリールイミンを製造する、請求項2の方法。
- R1は、フェニル、4-クロロフェニル、4-フルオロフェニル、4-ブロモフェニル、3-ニトロフェニル、2-メトキシフェニル、2-メチルフェニル、3-メチルフェニル、4-メチルフェニル、4-エチルフェニル、2-メチル-3-メトキシフェニル、2,4-ジブロモフェニル、3,5-ジフルオロフェニル、3,5-ジメチルフェニル、2,4,6-トリクロロフェニル、4-メトキシフェニル、ナフチル、2-クロロナフチル、2,4-ジメトキシフェニル、4-(トリフルオロメチル)フェニル、または2-ヨード-4-メチルフェニルから選択されるアリール基であり;およびアリール基は、C1-C10アルキル、ハロ、シアノ、ヒドロキシまたはフェニルから選択される1つまたは複数の独立した置換基で任意に置換される、請求項1-3のいずれか1項の方法。
- R1は、2-、3-または4-ピリジニル、ピラジニル、2-、4-もしくは5-ピリミジニル、ピリダジニル、トリアゾリル、テトラゾリル、イミダゾリル、2-もしくは3-チエニル、2-もしくは3-フリル、ピロリル、オキサゾリル、イソオキサゾリル、チアゾリル、イソチアゾリル、オキサジアゾリル、チアジアゾリル、キノリル、イソキノリル、ベンズイミダゾリル、ベンゾトリアゾリル、ベンゾフラニルまたはベンゾチエニルから選択されるヘテロアリール基であり;およびヘテロアリール基は、C1-C10アルキル、ハロ、シアノ、ヒドロキシまたはフェニルから選択される1つまたは複数の独立した置換基で任意に置換される、請求項1-3のいずれか1項の方法。
- R1は、2-フェニルキノリンである、請求項1-3のいずれか1項の方法。
- 少なくとも約0.5molの式Iが、少なくとも約50%の方法についての全体の収率において得られる、請求項1-6のいずれか1項の方法。
- (a)のための反応溶媒は、テトラヒドロフランまたは1,4-ジオキサンを含む、請求項2-7のいずれか1項の方法。
- 反応Aを使用してジアリールイミンを製造し、かつ有機塩基およびルイス酸の存在下において実施される、請求項2または4-8のいずれか1項の方法。
- 反応Aにおける有機塩基は、トリエチルアミンまたはN-メチルモルホリンを含む、請求項9の方法。
- ルイス酸は、四塩化チタンを含む、請求項9または10の方法。
- 2,3-ジクロロピラジンとジアリールイミンの反応は、tert-ブトキシドまたは金属ヘキサメチルジシルアジドの存在下において実施される、請求項1-11のいずれか1項の方法。
- R2は、メチル、エチル、n-プロピル、イソプロピル、n-ブチル、sec-ブチル、イソブチル、tert-ブチル、n-ペンチル、イソペンチル、n-ヘキシル、n-ヘプチル、イソオクチル、ノニル、デシルから選択され、これらのいずれもがC1-C10アルキル、ハロ、シアノ、ヒドロキシまたはフェニルから選択される1つまたは複数の独立した置換基によって置換することができる、請求項13の方法。
- R2は、メチルである、請求項13の方法。
- 少なくとも約0.5molの式Iが、少なくとも約50%の方法についての全体の収率において得られる、請求項13-15のいずれか1項の方法。
- 反応Cは、トリエチルアミンまたはエチルジイソプロピルアミンの存在下において実施される、請求項13-16のいずれか1項の方法。
- (b)のための塩基は、炭酸カリウムまたは炭酸セシウムを含む、請求項13-17のいずれか1項の方法。
- 工程(b)は、約40〜60℃の温度にて実施される、請求項13-18のいずれか1項の方法。
- (c)は、水酸化カリウム、水酸化ナトリウムまたは水酸化リチウムの存在下において実施される、請求項13-18のいずれか1項の方法。
- (c)は、塩酸、トリフルオロ酢酸、酢酸または硫酸の存在下において実施される、請求項13-18のいずれか1項の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17091109P | 2009-04-20 | 2009-04-20 | |
US61/170,911 | 2009-04-20 | ||
PCT/US2010/031547 WO2010123792A1 (en) | 2009-04-20 | 2010-04-19 | Preparation of c-pyrazine-methylamines |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012524119A true JP2012524119A (ja) | 2012-10-11 |
JP2012524119A5 JP2012524119A5 (ja) | 2013-04-25 |
Family
ID=42269933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012507282A Pending JP2012524119A (ja) | 2009-04-20 | 2010-04-19 | C−ピラジン−メチルアミンの調製 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8513415B2 (ja) |
EP (1) | EP2421837A1 (ja) |
JP (1) | JP2012524119A (ja) |
KR (1) | KR20120020099A (ja) |
CN (1) | CN102405214A (ja) |
BR (1) | BRPI1016245A2 (ja) |
CA (1) | CA2752826A1 (ja) |
MX (1) | MX2011011025A (ja) |
WO (1) | WO2010123792A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1740591E (pt) | 2004-04-02 | 2009-09-24 | Osi Pharm Inc | Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6 |
US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
CN103214424B (zh) * | 2013-04-25 | 2015-05-13 | 兰州康寓信生物科技有限公司 | 吡嗪甲胺衍生物的合成方法 |
ES2644784T3 (es) | 2013-08-08 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso |
WO2016087342A1 (de) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung |
EP3286185A1 (de) | 2015-02-05 | 2018-02-28 | Bayer Pharma Aktiengesellschaft | Substituierte pyrazolo[1,5-a]pyridin-3-carboxamide und ihre verwendung |
CN109553570A (zh) * | 2017-09-27 | 2019-04-02 | 胜兴化工(上海)有限公司 | 3-氯-5-三氟甲基-2-吡啶甲胺盐的制备方法 |
CN109182286B (zh) * | 2018-09-21 | 2021-07-30 | 泰州学院 | 一种改进的氰基还原酶及其在合成3-氯吡嗪-2甲胺中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0673026A (ja) * | 1992-04-28 | 1994-03-15 | Koei Chem Co Ltd | クロロピラジン類の製造法 |
JP2006514075A (ja) * | 2002-11-20 | 2006-04-27 | バイエル・クロツプサイエンス・エス・アー | 2−アミノメチルピリジン誘導体の製造方法 |
JP2007509060A (ja) * | 2003-10-15 | 2007-04-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
WO2007070826A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
WO2007079164A2 (en) * | 2005-12-29 | 2007-07-12 | Abbott Laboratories | Protein kinase inhibitors |
JP2007531754A (ja) * | 2004-04-02 | 2007-11-08 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 6,6−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤 |
JP2008105970A (ja) * | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791025A (fr) | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | Composes heterocycliques |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
EP0586608A1 (en) | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
JP2914407B2 (ja) | 1991-09-11 | 1999-06-28 | 富士電機株式会社 | 自動販売機 |
MX9304801A (es) | 1992-08-06 | 1997-06-28 | Warner Lambert Co | 2-toindoles (selenoidoles) disulfuros (seleniduros) relacinados, los cuales inhiben a las proteinas tirosina cinasas y los cuales tienen propiedades anti-tumorales. |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
EP2042194A3 (en) | 1999-05-14 | 2009-04-22 | Imclone Systems, Inc. | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
CA2380904C (en) | 1999-08-12 | 2009-02-10 | American Cyanamid Company | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
WO2002045653A2 (en) | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
AU2002219221B2 (en) | 2001-01-09 | 2007-05-17 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
EP1381598A4 (en) | 2001-03-28 | 2008-03-19 | Bristol Myers Squibb Co | NEW INHIBITORS OF TYROSINE KINASE |
BR0209147A (pt) | 2001-05-08 | 2004-06-08 | Merck Patent Gmbh | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
SE0102168D0 (sv) | 2001-06-19 | 2001-06-19 | Karolinska Innovations Ab | New use and new compounds |
AU2002315389A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
GB0122560D0 (en) | 2001-09-19 | 2001-11-07 | Aventis Pharma Ltd | Chemical compounds |
ATE420879T1 (de) | 2001-09-19 | 2009-01-15 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20030175763A1 (en) | 2001-12-20 | 2003-09-18 | Degenhardt Yan Y. | Identification of an amplified gene and target for drug intervention |
US20050215564A1 (en) | 2002-02-14 | 2005-09-29 | Stiles Charles D | Methods and compositions for treating hyperproliferative conditions |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
ATE353650T1 (de) | 2002-04-16 | 2007-03-15 | Astrazeneca Ab | Kombinationstherapie zur behandlung von krebs |
DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
WO2004014368A1 (en) | 2002-08-12 | 2004-02-19 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
DE10254853A1 (de) | 2002-11-25 | 2004-06-03 | Basf Ag | Verbessertes Verfahren zur Herstellung von Cyclopentenonen |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
PL378749A1 (pl) | 2003-03-12 | 2006-05-15 | Pfizer Products Inc. | Azabicykliczne pochodne pirydyloksymetylowe i benzoizoksazolowe |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
TW200526684A (en) | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
JP2007514759A (ja) | 2003-12-19 | 2007-06-07 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
RU2006143842A (ru) * | 2004-05-13 | 2008-08-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Новые замещенные тиофенкарбоксамиды, их получение и их применение в качестве лекарственных средств |
EP1758601A1 (en) | 2004-06-03 | 2007-03-07 | F.Hoffmann-La Roche Ag | Treatment with cisplatin and an egfr-inhibitor |
CA2572314A1 (en) | 2004-06-29 | 2006-01-12 | Christopher N. Farthing | Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
WO2006033001A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
US20070149567A1 (en) | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
DE202005016343U1 (de) | 2005-10-19 | 2007-02-22 | Weidmüller Interface GmbH & Co. KG | Elektrische Steckverbindung mit Schnellentriegelung |
JP5335432B2 (ja) | 2005-11-17 | 2013-11-06 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | 縮合2環系mTOR阻害剤 |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
WO2007075554A2 (en) | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
TW200738725A (en) | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
US7651687B2 (en) | 2006-03-13 | 2010-01-26 | Osi Pharmaceuticals, Inc. | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
KR20090026288A (ko) | 2006-05-31 | 2009-03-12 | 갈라파고스 엔.브이. | 퇴행성 및 염증성 질환의 치료에 유용한 트리아졸로피라진 화합물 |
DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
TW200900070A (en) | 2007-02-27 | 2009-01-01 | Osi Pharm Inc | Combination cancer therapy |
WO2009009016A1 (en) | 2007-07-06 | 2009-01-15 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
EP2178563A2 (en) | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
JP2010540960A (ja) | 2007-10-03 | 2010-12-24 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | インスリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌反応を予測する生物学的マーカー |
WO2009091939A1 (en) | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
ES2396613T3 (es) | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
CN102481361B (zh) | 2009-04-16 | 2014-10-22 | 默沙东公司 | 用于治疗癌症的组合物和方法 |
EP2427192A1 (en) | 2009-05-07 | 2012-03-14 | OSI Pharmaceuticals, LLC | Use of osi-906 for treating adrenocortical carcinoma |
US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP2013529641A (ja) | 2010-06-23 | 2013-07-22 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Osi−906の多形体 |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
-
2010
- 2010-04-19 WO PCT/US2010/031547 patent/WO2010123792A1/en active Application Filing
- 2010-04-19 US US13/265,363 patent/US8513415B2/en not_active Expired - Fee Related
- 2010-04-19 MX MX2011011025A patent/MX2011011025A/es not_active Application Discontinuation
- 2010-04-19 KR KR1020117020844A patent/KR20120020099A/ko not_active Application Discontinuation
- 2010-04-19 BR BRPI1016245-3A patent/BRPI1016245A2/pt not_active IP Right Cessation
- 2010-04-19 CA CA2752826A patent/CA2752826A1/en not_active Abandoned
- 2010-04-19 CN CN2010800174272A patent/CN102405214A/zh active Pending
- 2010-04-19 EP EP10714546A patent/EP2421837A1/en not_active Withdrawn
- 2010-04-19 JP JP2012507282A patent/JP2012524119A/ja active Pending
-
2013
- 2013-05-23 US US13/901,054 patent/US20130261306A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0673026A (ja) * | 1992-04-28 | 1994-03-15 | Koei Chem Co Ltd | クロロピラジン類の製造法 |
JP2006514075A (ja) * | 2002-11-20 | 2006-04-27 | バイエル・クロツプサイエンス・エス・アー | 2−アミノメチルピリジン誘導体の製造方法 |
JP2007509060A (ja) * | 2003-10-15 | 2007-04-12 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
JP2007531754A (ja) * | 2004-04-02 | 2007-11-08 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 6,6−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤 |
WO2007070826A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
WO2007079164A2 (en) * | 2005-12-29 | 2007-07-12 | Abbott Laboratories | Protein kinase inhibitors |
JP2008105970A (ja) * | 2006-10-24 | 2008-05-08 | Ohara Yakuhin Kogyo Kk | ジヒドロキノリン誘導体の製造方法及びその中間体 |
Non-Patent Citations (1)
Title |
---|
JPN7014001354; HARTZ,R. A.,ET AL.: '"Synthesis and Evaluation of Imidazo[1,5-a]pyrazines as Corticotropin Releasing Hormone Receptor Lig' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS VOL.12,NO.3, 2002, PP.291-294 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010123792A1 (en) | 2010-10-28 |
KR20120020099A (ko) | 2012-03-07 |
US20130261306A1 (en) | 2013-10-03 |
EP2421837A1 (en) | 2012-02-29 |
BRPI1016245A2 (pt) | 2015-09-01 |
US8513415B2 (en) | 2013-08-20 |
US20120041202A1 (en) | 2012-02-16 |
CA2752826A1 (en) | 2010-10-28 |
CN102405214A (zh) | 2012-04-04 |
MX2011011025A (es) | 2011-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012524119A (ja) | C−ピラジン−メチルアミンの調製 | |
JP6691115B2 (ja) | コパンリシブおよびそれの二塩酸塩の合成 | |
TWI697494B (zh) | 科帕利普(copanlisib)及其二鹽酸鹽之合成 | |
US11708362B2 (en) | Process for preparing aminopyrimidine derivatives | |
US9890159B2 (en) | Process for making duocarmycin prodrugs | |
JP5049946B2 (ja) | β−アドレナリン受容体のアゴニストとして有用なアリールエタノールジアミンの製造方法 | |
JP2012532882A (ja) | 置換3−アミノ−5−オキソ−4,5−ジヒドロ−[1,2,4]トリアジンのための製法 | |
JP5570524B2 (ja) | 5−ホルミル−ピリジン−2,3−ジカルボン酸エステルの製造方法 | |
US20230128639A1 (en) | Process for preparing soluble guanylate cyclase stimulators | |
IL271974B (en) | New intermediates useful for the synthesis of aminopyrimidine derivatives, a process for their preparation and a process for preparing aminopyrimidine derivatives using them | |
WO2011093365A1 (ja) | 含窒素複素環化合物 | |
TWI830876B (zh) | 6-(1-丙烯醯基呱啶-4-基)-2-(4-苯氧基苯基)尼克醯胺的製備工藝 | |
US8236954B2 (en) | Processes for preparing benzimidazole thiophenes | |
US20070293678A1 (en) | Process For The Preparation Of 6, 8-Subs Tituted '1, 7 Naphthpyridin Derivatives By Reacting The 8-Halo-'1, 7 Naphthpyrid In-Derivate With An Organic Boronic Acid Derivatives And Intermadiates Of This Process | |
Mamedov et al. | 3-(α-azidoalkyl) quinoxalin-2 (1H)-ones and related alkylquinoxalinyl ketones | |
CN111303160A (zh) | 一种取代吡咯并嘧啶中间体的制备方法 | |
CN115745956A (zh) | 一种3-溴-1-(3-氯-2-吡啶基)-1氢-吡唑-5-甲酸的合成方法 | |
EP3870568A1 (en) | Process for the preparation of rilpivirine | |
CN1290247A (zh) | 制备抗叶酸剂的方法和中间体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130306 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140502 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140708 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140715 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150123 |